diet physical*sustained weight loss*weight weekly*weight maintenance program*medical care setting*diet choice*comprehensive weight maintenance*total meal replacement*baseline body weight*maintenance counseling*weight maintenance counseling*loss such program*comprehensive weight*comprehensive weight loss*monthly contact*weight loss maintenance*loss sustained weight*term weight loss*diet physical activity*intensive behavioral lifestyle*loss maintenance program*behavioral lifestyle*body weight weekly*necessary energy deficit*least monthly contact*total meal*trained practitioner*baseline body*trained interventionists*close medical monitoring*behavioral lifestyle intervention*trained interventionist*weight loss goal*short term weight
longer study*weight loss treatment*pharmacological therapy*weight management program*lifelong lifestyle*comprehensive weight management*metabolic surgery*effective weight loss*nonsurgical subject*lifelong lifestyle support*optimal medical therapy*comprehensive weight*metabolic profile
aglucosidase*tolerability issue*diet physical*loss medication*successful weight loss*diet physical activity*glucose lowering medication*insufficient weight loss*alpha glucosidase*diabetes provider*possible medication*aglucosidase inhibitor*weight loss medication
lower gfr range*counseling setting*filtration rate gfr*rate gfr*longstanding evidence*min week minimum*goal metformin*longstanding evidence base*min week*physical activity goal*goal metformin monotherapy*glycemic goal*lifestyle effort*lower gfr*glomerular filtration rate*glycemic goal metformin*metformin monotherapy*ml min*gfr range
loss ketosis*ongoing glycemia reduction*inhibitor glp1 analog*glycemic effect*inhibitor glp1*sulfonylurea dpp4*dpp4 inhibitor glp1*comparative effectiveness study*moderate glycemic effect*glucose toxicity*catabolic feature weight*postprandial hypoglycemia*study grade*reduction approach*glp1 analog*dpp4 inhibitor*secretagogues meglitinides*feature weight loss*late postprandial hypoglycemia*class sulfonylurea dpp4*effectiveness study grade*health economic outcome*weight loss ketosis*irregular meal*ongoing glycemia*class sulfonylurea*glp 1*feature weight*moderate glycemic*catabolic feature*glucagon like peptide*effectiveness study*glycemia reduction*irregular meal schedule*medical psychosocial*meal schedule*glp1*drug class sulfonylurea*glycemia reduction approach*major drug class*sulfonylurea dpp4 inhibitor
noninsulin agent*insulin analog*inhibitor glp1*sulfonylurea dpp4*acceptable fasting*concentrated preparation*glycemic goal*dpp4 inhibitor glp1*dosing range*glp1 receptor*glycemic goal provider*initiate insulin therapy*limited dosing range*injectable therapy*pharmacodynamic profile*dpp4 inhibitor*initiate insulin*glp1 receptor agonist*combination injectable therapy*noninsulin*u200*insulin regimen*serial lung function*insulin analog people*complex insulin regimen*postprandial glucose excursion*part mix*u300 glargine*suboptimal blood glucose*glp 1*blood glucose control*postprandial glucose*acceptable fasting blood*suboptimal blood*glucagon like peptide*u300*regimen flexibility*complex insulin*dos adjunctive use*glucose excursion*adjunctive use*analog people*limited dosing*prandial use*glp1*basal insulin analog*bolus insulin dosing*serial lung*u200 degludec*goal provider*lung function testing*sulfonylurea dpp4 inhibitor
min week
